Exploring the Shift: Transitioning from Semaglutide to Tirzepatide
Switching from semaglutide to tirzepatide may enhance diabetes and weight management. Tirzepatide, a dual agonist of GLP-1 and GIP receptors, offers potentially improved outcomes compared to semaglutide, a GLP-1 receptor agonist. Consultation with healthcare providers ensures proper adjustment and monitoring for side effects.


